This is an open-label study of patients with relapsing forms of Multiple Sclerosis designed
to assess the longitudinal pharmacokinetic, pharmacodynamic, immunological, and biochemical
sample collection with MRI and relapse analysis of a Tysabri patient cohort. The study hopes
to identify secondary and tertiary risk stratification markers that would aid in the clinical
management of patients who are JC antibody positive.